| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.078 | 0.2 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |